Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

ANI Pharmaceuticals Forecasts 2024 Revenues Of $520M-$542M, With Adjusted EPS Of $4.26 to $4.67 Versus Consensus Of $506.16M And $4.33, Respectively

Author: Benzinga Newsdesk | February 29, 2024 07:54am

Posted In: ANIP